StockData

Curis vs Innate Pharma

CRIS and IPHA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

crisCuris$0.59−97.7% in 1 yeariphaInnate Pharma$1.59−30.9% in 1 year

How CRIS and IPHA compare

Innate Pharma grew revenue faster over the last twelve months (−55.2% versus −62.2% for Curis).

Curis scores higher on the StockData Score (7 against 0 for Innate Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCRISIPHA
Size and price
Market cap$1.2M–
Share price$0.592$1.59
Change, 1 year−97.7%−30.9%
Change, 5 years−100.0%−68.3%
Beta (5Y)1.950.95
Employees24181
StockData Score
Total score7 (better)0
Valuation score3 (better)0
Growth score00
Performance score00
Health score4 (better)0
Dividend score00
Valuation
P/S0.3×–
P/B0.3×–
Fair value$6.77–
Margin of safety91.3%–
Growth
Revenue growth (TTM)−62.2%−55.2% (better)
Revenue growth, 5Y average−2.7% (better)−33.6%
Profitability
Operating margin−203% (better)−600%
Net margin−490%–
FCF margin–−587%
Financial health
Debt / equity0.00–
Interest coverage–−17.3×
Current ratio0.490.60 (better)
Altman Z-score−96.16–
Piotroski F-score3–
Dividends and buybacks
Buyback yield−1989%–
Shareholder yield−1989%–
Ownership
Held by institutions32.1%0.21%
Held by insiders20.4%16.2%
Insider net buying, 12 months$5.5K–
Short interest, % of float61.8%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.